Novartis considers “pay-for-performance” for CAR-T – pharmaphorum
pharmaphorum |
Novartis considers “pay-for-performance” for CAR–T
pharmaphorum Novartis is considering a “pay-for-performance” pricing scheme if its CAR–T therapy gets approved, following trial results published earlier this week. Results of the phase 2 JULIET study of 51 patients in relapsed or refractory diffuse large B-cell … CAR–T pricing decision looms large for NovartisThe Pharma Letter (registration) |
BioPharma-Reporter.com |
Lonza plugs EU cell and gene therapy manufacturing gap through PharmaCell buy
BioPharma-Reporter.com The deal sees Switzerland-headquartered contract development and manufacturing organisation (CDMO) add the assets and staff of PharmaCell to strengthen its cell and gene therapy offerings. “We had a manufacturing gap in the European market, … |
Science Daily |
World first: Stem cell treatment for lethal STAT1 gene mutation shows ‘disappointing,’ but promising results
Science Daily Dr. Okada, who first discovered the STAT1 gain of function mutation in 2011, says that “Overall, this result is disappointing — but the fact five patients were cured proves that treatment with stem cells can work, and we now need to learn from these … |
|
CRISPR pioneer Feng Zhang’s lab spawns a new Cambridge biotech
Boston Business Journal They include Zhang, a co-inventor of CRISPR/Cas9, the experimental and potentially revolutionary technology for cutting out and replacing parts of genes. Two graduate students who work in Zhang’s lab and have conducted research related to CRISPR, … |
|
Synthetic Biology Market to grow at a CAGR of 23%, Globally, by 2020
Medgadget (blog) Synthetic Biology Market Report, published by Allied Market Research, forecasts that the global market was valued to be $5.2 billion in 2015 and is expected to grow a CAGR of 23% during the period 2015 – 2020.Nucleotide synthesis and sequencing … |